dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Panisello, Carla |
dc.contributor.author | Tirtakasuma, Ricky |
dc.contributor.author | Díaz-Gómez, Judit |
dc.contributor.author | Grases Mendoza, Daniela |
dc.contributor.author | Pasamar Garijo, Helena |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Gos, Alena |
dc.contributor.author | Palomero, Jara |
dc.contributor.author | Lozano Rabella, Maria |
dc.date.accessioned | 2023-02-01T13:10:47Z |
dc.date.available | 2023-02-01T13:10:47Z |
dc.date.issued | 2022-12 |
dc.identifier.citation | Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Díaz-Gómez J, Grases D, et al. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. J Immunother Cancer. 2022 Dec;10(12):e005443. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/8948 |
dc.description | Neoplàsies genitals; Immunoteràpia; Limfòcits T |
dc.description.sponsorship | AG was funded by the Comprehensive Program of Cancer Immunotherapy and Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021), the La Fundació La Marató de TV3 (201919-30; identification number 488/C/2019), the Spanish Ministry of Science and Innovation (PID2020-118529RB-100) and Instituto de Salud Carlos III (CP15/00058). We thank the CERCA Programme/Generalitat de Catalunya for institutional support. JP was supported by the Beatriu de Pinós programme (BP 2018), cofounded by the Agency for Management of University and Research Grants (AGAUR) and European Union's Horizon 2020. HUB-ICO-IDIBELL Biobank received support from Instituto de Salud Carlos III (PT20/00171) and by Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya (XBTC). |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;10(12) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Endometri - Càncer - Prognosi |
dc.subject | Marcadors tumorals |
dc.subject.mesh | Biomarkers, Tumor |
dc.subject.mesh | Endometrial Neoplasms |
dc.subject.mesh | Prognosis |
dc.title | Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2022-005443 |
dc.subject.decs | marcadores tumorales |
dc.subject.decs | neoplasias endometriales |
dc.subject.decs | pronóstico |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2022-005443 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Díaz-Gómez J, Grases D, Pasamar H, Gros A] Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 36581331 |
dc.identifier.wos | 000905619800001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PID2020-118529RB-100 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |